Endocrine Abstracts

Objective: Cushing’s disease (CD) accounts for approximately 80% of cases of Cushing’s syndrome. Its clinic is nonspecific and its diagnosis difficult. The objective of this study is to review the most frequent clinical signs of this disease in our environment and compare it with that described in the literature.Patients and methods: Retrospective descriptive study of patients with CD. We included all patients diagnosed with CD (2005–2017)...

Objective: Cushing’s disease (CD) accounts for approximately 80% of cases of Cushing’s syndrome. Diagnosis of CD is difficult, it is carried out with a screening test and confirmation test. The aim of this study is to describe the diagnostic results of the different diagnostic tests used in the diagnosis of CD in our environment.Patients and methods: Retrospective descriptive study of patients with CD. We included all patients diagnosed with CD...

Objective: The most used therapeutic guidelines for the induction of male puberty in hypogonadotropic hypogonadism (HH) are GnRH in subcutaneous pulsatile infusion and HCG in monotherapy or combined with FSH in intramuscular injection. The objective of this study was to evaluate the efficacy of subcutaneous HCG with or without FSH in induction of male puberty in patients with HH.Patients and methods: Descriptive study of patients with HH treated with HCG...

Background: Acromegaly is the consequence of excessive growth hormone (GH) secretion, usually produced by a pituitary adenoma. Transphenoidal surgery is the first-choice treatment; however, the development of new drug therapies in the last years, specially the somatostatin analogues (SSA), has open new and promising avenues for the treatment of pituitary tumors.Objective: To determine whether a detailed knowledge of the clinico-pathological and radiologi...

Objective: The aim of this study was to evaluate maternal and neonatal outcomes in women with type 1 diabetes mellitus (DM1), and analysing differences associated to insulin glargine exposure during pregnancy.Patients and methods: Retrospective descriptive study of pregnancies in women with DM1 (2004–2012). Variables analysed: baseline characteristics (age, time of diabetes evolution, microvascular complications, and weight), maternal outcomes (weig...

Objective: The aim of this study was to determine the prevalence of pregnancy planning in women with type 1 diabetes mellitus (DM1) and analysing differences associated with unplanned pregnancy.Patients and methods: Retrospective descriptive study of pregnancies in women with DM1 (2004–2012). Variables analysed: age, time of diabetes evolution, microvascular complications, and maternal outcomes (HbA1c, preeclampsia, abortions, and Caesarean section)...

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Our objective was to describe the characteristics of these patients and their glycemic control expressed as HbA1c and times in range. Methods and patientsObservational longitudinal clinical study between January 2021 and December 2021 in patients with DM1 between 14 and 18 years. Results 95 patients included. Mean age: 16.64 ± 1.25 years, with a mean DM evolution time of 6.46 ± 3....